Lidocaine topical gel - Mayfield Pharmaceuticals
Alternative Names: MAY 44Latest Information Update: 28 Mar 2022
At a glance
- Originator Elle Pharmaceutical
- Developer Elle Pharmaceutical; Mayfield Pharmaceuticals
- Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dyspareunia
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for clinical-Phase-Unknown development in Dyspareunia in USA (Topical, Gel)
- 31 May 2021 Harrow Health and Mayfield Pharmaceuticals terminates asset purchase agreement and outstanding agreements with Elle Pharmaceutical
- 07 Feb 2019 Elle Pharmaceutical has patent protection for 'Aqueous gel composition and methods of use' in USA prior to February 2019